Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/107426
DC FieldValueLanguage
dc.contributor.authorAlves, Américo J. S.-
dc.contributor.authorAlves, Nuno G.-
dc.contributor.authorLaranjo, Mafalda-
dc.contributor.authorGomes, Clara S. B.-
dc.contributor.authorGonçalves, Ana Cristina-
dc.contributor.authorRibeiro, Ana Bela Sarmento-
dc.contributor.authorBotelho, M. Filomena-
dc.contributor.authorPinho e Melo, Teresa M. V. D.-
dc.date.accessioned2023-07-11T08:34:14Z-
dc.date.available2023-07-11T08:34:14Z-
dc.date.issued2022-06-01-
dc.identifier.issn09680896pt
dc.identifier.urihttps://hdl.handle.net/10316/107426-
dc.description.abstractChiral alkylidene-β-lactams and alkylidene-γ-lactams were synthesized and screened for their in vitro activity against four human cancer cell lines (melanoma, esophageal, lung and fibrosarcoma carcinoma). Alkylidene-β-lactams were synthesized via Wittig reaction of diverse phosphorus ylides with benzhydryl 6-oxopenicillanate, derived from 6-aminopenicillanic acid. Moreover, novel chiral alkylidene-γ-lactams were synthesized through a multistep strategy starting from a chiral substrate (d-penicillamine). The in vitro assays allowed the identification of four compounds with IC50 values < 10 μM for A375 cell line, and three compounds with IC50 values < 10 μM for OE19 cell line. The effect of the most promising compounds on cell death mechanism, reactive oxygen species generation as well as the evaluation of their ability to act as MMP-9 inhibitors were studied. The reported results unveil the potential of alkylidene-β-lactams as anticancer agents.pt
dc.language.isoengpt
dc.publisherElsevierpt
dc.relationLA/P/0008/2020pt
dc.relationLA/P/0140/2020pt
dc.relationinfo:eu-repo/grantAgreement/FCT/3599-PPCDT/RECI/BBB-BEP/0124/2012/PT/Modern Structural Biology: Resources for the advancement of in-house X-ray Crystallographypt
dc.relationinfo:eu-repo/grantAgreement/FCT/OE/SFRH/BD/128910/2017/PT/Novel spiro-lactams as new antimicrobial agentspt
dc.relationinfo:eu-repo/grantAgreement/UIDP/04539/2020pt
dc.relationUIDB/50006/2020pt
dc.relationUIDP/50006/2020pt
dc.relationUIDB/04378/2020pt
dc.relationUIDB/04539/2020pt
dc.relationUIDB/00313/2020pt
dc.relationUIDP/00313/2020pt
dc.relationUIDP/04378/2020pt
dc.relationinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UID/NEU/04539/2019/PTpt
dc.rightsembargoedAccesspt
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt
dc.subjectAlkylidene-β-lactampt
dc.subjectAlkylidene-γ-lactampt
dc.subjectAnticancer agentspt
dc.subjectEsophageal cancerpt
dc.subjectFibrosarcomapt
dc.subjectLung cancerpt
dc.subjectMelanomapt
dc.subjectPenicillanatespt
dc.subject.meshCell Linept
dc.subject.meshHumanspt
dc.subject.meshLactamspt
dc.subject.meshbeta-Lactamspt
dc.subject.meshAntineoplastic Agentspt
dc.subject.meshNeoplasmspt
dc.titleInsights into the anticancer activity of chiral alkylidene-β-lactams and alkylidene-γ-lactams: Synthesis and biological investigationpt
dc.typearticle-
degois.publication.firstPage116738pt
degois.publication.titleBioorganic & Medicinal Chemistrypt
dc.peerreviewedyespt
dc.identifier.doi10.1016/j.bmc.2022.116738pt
degois.publication.volume63pt
dc.date.embargo2023-06-01*
uc.date.periodoEmbargo365pt
item.grantfulltextopen-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextCom Texto completo-
item.openairetypearticle-
item.cerifentitytypePublications-
item.languageiso639-1en-
crisitem.author.researchunitCQC - Coimbra Chemistry Centre-
crisitem.author.researchunitCQC - Coimbra Chemistry Centre-
crisitem.author.researchunitCNC - Center for Neuroscience and Cell Biology-
crisitem.author.researchunitCNC - Center for Neuroscience and Cell Biology-
crisitem.author.researchunitCQC - Coimbra Chemistry Centre-
crisitem.author.parentresearchunitFaculty of Sciences and Technology-
crisitem.author.parentresearchunitFaculty of Sciences and Technology-
crisitem.author.parentresearchunitFaculty of Sciences and Technology-
crisitem.author.orcid0000-0003-0689-6007-
crisitem.author.orcid0000-0003-3672-0045-
crisitem.author.orcid0000-0003-1470-4802-
crisitem.author.orcid0000-0002-4142-4841-
crisitem.author.orcid0000-0001-7202-1650-
crisitem.author.orcid0000-0003-3256-4954-
crisitem.project.grantnoCenter for Innovative Biomedicine and Biotechnology-
crisitem.project.grantnoAssociated Laboratory for Green Chemistry - Clean Technologies and Processes- REQUIMTE-
crisitem.project.grantnoAssociated Laboratory for Green Chemistry - Clean Technologies and Processes-
crisitem.project.grantnoApplied Molecular Biosciences Unit - UCIBIO-
crisitem.project.grantnoCenter for Innovative Biomedicine and Biotechnology - CIBB-
crisitem.project.grantnoCoimbra Chemistry Center-
crisitem.project.grantnoCoimbra Chemistry Center-
crisitem.project.grantnoApplied Molecular Biosciences Unit-
crisitem.project.grantnoCNC. IBILI-
Appears in Collections:FMUC Medicina - Artigos em Revistas Internacionais
I&D CIBB - Artigos em Revistas Internacionais
I&D ICBR - Artigos em Revistas Internacionais
I&D CQC - Artigos em Revistas Internacionais
Files in This Item:
File Description SizeFormat
Alves2022BioorgMedChem.pdf909.59 kBAdobe PDFView/Open
Show simple item record

SCOPUSTM   
Citations

4
checked on Jun 10, 2024

WEB OF SCIENCETM
Citations

2
checked on Jun 2, 2024

Page view(s)

168
checked on Oct 30, 2024

Download(s)

83
checked on Oct 30, 2024

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons